Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

Patent metadata

Field	Value
Publication number	US-10434112-B2
Application number	US-201715490127-A
Country	US
Kind code	B2
Filing date	Apr 18, 2017
Priority date	Mar 6, 2013
Publication date	Oct 8, 2019
Grant date	Oct 8, 2019

Abstract

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).

First claim

What is claimed is:

1. A method of treating dermal inflammation or a dermal disease in a subject in need of such treatment, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a formyl peptide receptor 2 (FPR2) agonist of Formula II:

wherein:
a is 1 and b is 0;
a is 0 and b is 1; or
a is 1 and b is 1;
R 1 is optionally substituted C 1-8 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl, optionally substituted C 3-8 cycloalkenyl, —NR 11 R 12 or —OR 13 ;
R 2 is optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 3 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl;
R 4 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl;
R 5 is halogen, —CF 3 or —S(O) n R 14 ;
n is 0, 1 or 2;
R 6 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl;
R 7 is hydrogen, optionally substituted C 1-8 alkyl, halogen, —COOR 15 , —OR 13 , —NR 11 R 12 , NO 2 , optionally substituted heterocycle, optionally substituted C 3-8 cycloalkyl, optionally substituted C 6-10 aryl or optionally substituted C 3-8 cycloalkenyl;
R 8 is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 9 is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 10 is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 9a is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 10a is hydrogen, optionally substituted C 1-8 alkyl or optionally substituted C 6-10 aryl;
R 11 is hydrogen or optionally substituted C 1-8 alkyl;
R 12 is hydrogen or optionally substituted C 1-8 alkyl;
R 13 is hydrogen or optionally substituted C 1-8 alkyl;
R 14 is hydrogen, CF 3 or optionally substituted C 1-8 alkyl; and
R 15 is hydrogen or optionally substituted C 1-8 alkyl;
or a pharmaceutically acceptable salt thereof;
wherein the dermal inflammation or dermal disease is selected from the group consisting of dermal wound healing, hypertrophic scars, keloids, burns, rosacea, atopic dermatitis, acne, psoriasis, seborrheic dermatitis, actinic keratoses, basal cell carcinoma, squamous cell carcinoma, melanoma, viral warts, photoaging, photodamage, melasma, post-inflammatory hyperpigmentation, disorders of pigmentation and alopecia, scarring and non-scarring forms;
and wherein the administration is by local delivery.

2. The method of claim 1 , wherein the FPR2 agonist is a compound selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the local delivery is topical dermal delivery.

4. The method of claim 3 , wherein the pharmaceutical composition is in a form selected from the group consisting of a cream, a lotion, a gel, a solution, a spray, a foam, a suspension and an emulsion.

Assignees

• Allergan Inc

Inventors

• Viswanath Veena
• Beard Richard L
• Donello John E
• Hsia Edward

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/41

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• A61K31/683 Primary

  Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols · CPC title

• A61P17/14

  for baldness or alopecia · CPC title

• A61K31/196 Primary

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title